MAPT and Alzheimer disease: Overwhelming evidence has shown that not only does plasma NfL significantly increase in AD compared to controls, but it also correlates with CSF NfL and tau biomarkers (Mattsson et al., 2017; Lewczuk et al., 2018; Lin et al., 2018).